Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections | NEJM

Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections | NEJM

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in Wuhan, China, in December 2019. As of November 24, 2021, SARS-CoV-2 has infected more than 259 million people and caused more than 5.19 million deaths worldwide. At present, vaccines are the primary preventative measure that can be taken to protect individuals against coronavirus disease 2019 (COVID-19). However, due to the emergence of SARS-CoV-2 variants, vaccine effectiveness has been threatened. Therefore, there remains an urgent need to develop easily usable, effective, and affordable prophylactics and treatment options. Since the pathogenesis of SARS-CoV-2 starts at the nasal cavity and rhinopharynx, many researchers believe that nasal sprays with antiviral properties may be an effective option to attack the virus and reduce the viral load. Study: Iota-carrageenan and xylitol inhibit SARS-CoV-2 in …
More on: www.news-medical.net